MedTrace Logo

Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years

NCT04622579 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-11-10

No results posted yet for this study

Summary

About 40% of Diffuse large B cell lymphoma relapse or is refractory, age is a prognostic factor of DLBCL, as elderly patients are not capable to received standard treatment, the prognosis of elderly patients is poor especially those aged over 80 years. In this study,we aimed to investigate the safety and efficacy of the combination of lenalidomide and rituximab in elderly patients aged ≥ 80 years with untreated DLBCL.

Conditions

Interventions

DRUG

lenalidomide combined with rituximab

lenalidomide and rituximab are dilivered as described, parameters concerning efficacy and safety are also obtained.

Sponsors & Collaborators

  • Guangzhou First People's Hospital

    collaborator OTHER

  • First People's Hospital of Foshan

    collaborator OTHER

  • Huizhou Municipal Central Hospital

    collaborator OTHER

  • Shantou Central Hospital

    collaborator OTHER

  • Guangdong Provincial People's Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-23
Primary Completion
2022-12-31
Completion
2023-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04622579 on ClinicalTrials.gov